International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(19), P. 10632 - 10632
Published: Oct. 2, 2024
Nanotechnology
is
transforming
therapeutics
for
brain
disorders,
especially
in
developing
drug
delivery
systems.
Intrathecal
immunoselective
nanopheresis
with
soluble
monoclonal
antibodies
represents
an
innovative
approach
the
realm
of
systems
Central
Nervous
System
conditions,
targeting
beta-amyloid
Alzheimer’s
disease.
This
review
delves
into
concept
intrathecal
nanopheresis.
It
provides
overall
description
devices
to
perform
this
technique
while
discussing
nanotechnology
behind
its
mechanism
action,
potential
advantages,
and
clinical
implications.
By
exploring
current
research
advancements,
we
aim
provide
a
comprehensive
understanding
novel
method,
addressing
critical
questions
what
it
is,
how
works,
why
needed,
when
should
be
applied.
Special
attention
given
patient
selection
optimal
timing
therapy
initiation
Alzheimer’s,
coinciding
peak
accumulation
amyloid
oligomers
early
stages.
Potential
limitations
alternative
targets
beyond
future
perspectives
are
also
described.
Frontiers in Materials,
Journal Year:
2024,
Volume and Issue:
11
Published: April 12, 2024
Disorders
of
the
central
nervous
system
(CNS)
constitute
a
significant
global
health
concern
at
moment.
Most
CNS
disorders
are
characterized
by
severe
neuronal
damage
with
excessive
production
reactive
oxygen
species,
which
induces
high
levels
oxidative
stress
and
intense
inflammatory
responses
in
affected
tissues,
thus
aggravating
disease
pathology.
Notably,
blood–brain
barrier
makes
it
difficult
to
deliver
many
drugs
biologics
CNS,
creates
great
difficulties
diagnosis
treatment
disorders.
Recent
research
on
polydopamine
nanotechnology
has
led
discovery
promising
properties;
shows
strong
scavenging
ability
for
prevents
activation
pro-inflammatory
microglia,
its
repair
function
can
reduce
brain
protect
neurons.
Moreover,
improve
permeability
their
neurotoxicity.
It
is
therefore
candidate
associated
stress.
In
present
paper,
we
review
functionality
as
well
potential
recent
advances
polydopamine-based
nanosystems
various
disorders,
including
Alzheimer’s
disease,
Parkinson’s
stroke,
spinal
cord
injury,
glioma.
Finally,
predict
how
nanoparticles
may
guide
future
therapeutic
strategies
address
such
epilepsy,
currently
have
no
cure.
The Innovation Life,
Journal Year:
2024,
Volume and Issue:
2(3), P. 100082 - 100082
Published: Jan. 1, 2024
<p>Previous
studies
have
revealed
the
existence
of
gut
epithelial-neuronal
synapses
and
an
array
neuroactive
bacterial
metabolites,
highlighting
potential
chemicals
in
stimulating
gut-to-brain
neurotransmission.
However,
metabolite-focused
murine
models
frequently
apply
systemic
administration
chemicals,
illustrated
signals
are
generally
through
humoral
pathways,
probably
distinct
from
physiological
working
mechanism,
since
many
metabolites
could
not
cross
blood-brain
barrier
primates.
Limited
by
delivery
approach,
research
on
neurotransmission
pathway
regulated
is
sparse.
To
address
this
challenge,
engineered
commensal
bacteria
were
harnessed
for
with
biogeography.
In
model
depression,
synthetic
butyrate-overproducing
<i>Escherichia
coli</i>
Nissle
1917
(EcN)
significantly
attenuates
depressive-like
syndromes.
The
aberrantly
activated
paraventricular
thalamus
(PVT)
modulated
butyrate
via
a
route,
which
illuminated
first
time.
We
provide
paradigm
dissecting
pathways
point
out
new
avenue
non-invasive
neuromodulation
oral
metabolically
bacteria,
without
dependence
external
devices
or
surgery.</p>
Nanomaterials,
Journal Year:
2024,
Volume and Issue:
14(17), P. 1379 - 1379
Published: Aug. 23, 2024
The
blood–brain
barrier
(BBB)
plays
a
vital
role
in
safeguarding
the
central
nervous
system
by
selectively
controlling
movement
of
substances
between
bloodstream
and
brain,
presenting
substantial
obstacle
for
administration
therapeutic
agents
to
brain.
Recent
breakthroughs
nanoparticle-based
delivery
systems,
particularly
metal–organic
frameworks
(MOFs),
provide
promising
solutions
addressing
BBB.
MOFs
have
become
valuable
tools
delivering
medications
brain
with
their
ability
efficiently
load
drugs,
release
them
over
time,
modify
surface
properties.
This
review
focuses
on
recent
advancements
molecular-based
approaches
treating
disorders,
such
as
glioblastoma
multiforme,
stroke,
Parkinson’s
disease,
Alzheimer’s
disease.
paper
highlights
significant
impact
overcoming
shortcomings
conventional
drug
techniques
provides
insights
future
research
field
neurotherapeutics.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(19), P. 10632 - 10632
Published: Oct. 2, 2024
Nanotechnology
is
transforming
therapeutics
for
brain
disorders,
especially
in
developing
drug
delivery
systems.
Intrathecal
immunoselective
nanopheresis
with
soluble
monoclonal
antibodies
represents
an
innovative
approach
the
realm
of
systems
Central
Nervous
System
conditions,
targeting
beta-amyloid
Alzheimer’s
disease.
This
review
delves
into
concept
intrathecal
nanopheresis.
It
provides
overall
description
devices
to
perform
this
technique
while
discussing
nanotechnology
behind
its
mechanism
action,
potential
advantages,
and
clinical
implications.
By
exploring
current
research
advancements,
we
aim
provide
a
comprehensive
understanding
novel
method,
addressing
critical
questions
what
it
is,
how
works,
why
needed,
when
should
be
applied.
Special
attention
given
patient
selection
optimal
timing
therapy
initiation
Alzheimer’s,
coinciding
peak
accumulation
amyloid
oligomers
early
stages.
Potential
limitations
alternative
targets
beyond
future
perspectives
are
also
described.
